PEBC Part I (MCQ) · Competency 1A Clinical Care (about 50% of Part I)
Pain and rheumatology items test analgesic choice and limits, opioid safety under the 2017 Canadian guideline, neuropathic pain, osteoarthritis, rheumatoid arthritis drug monitoring and gout management.
1A Clinical Care2 min read6 sections
Checked against the 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain (CMAJ 2017;189:E659); Canadian Pain Society neuropathic pain consensus (2014); 2020 ACR gout guideline; Canadian Rheumatology Association RA guidance; Health Canada acetaminophen, codeine and tramadol labelling; checked 13 Oct 2026. Not affiliated with or endorsed by The Pharmacy Examining Board of Canada (PEBC).
Items include opioid conversions and tapers, combination analgesic dosing, interaction checks and flare management in patients with CKD or coronary disease.
Convert via morphine equivalents (oxycodone 1.5, hydromorphone 5, codeine 0.15).
When switching, start at 50% or less of the calculated dose if the prior dose was high, 60-75% if moderate or low.
Taper slowly (about 5-10% every 2-4 weeks) with support; offer naloxone.
Start a stimulant laxative with regular opioids.
Every note. Every question. One pass.
4 more sections of this note are part of Premium.
From about C$16.58/mo on the Until-you-pass pass (12 months)
Educational practice material for exam preparation only. Not medical advice and not a substitute for current product monographs, clinical guidelines or professional judgement. Questions have not yet been reviewed by a licensed pharmacist.
